Tuvshinbayar N

State Second Central Hospital, Mongolia

Title: Clinical and virusological outcomes of tenofovir alafenamide treatment in patients with Hepatitis B virus infection

Abstract

Introduction:

WHO estimates that 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. The latest data shows that 10.6-11.6 % of Mongolian population are infected with hepatitis B virus infection.

Goal:

Evaluate the clinical and virological outcome of tenofovir alafenamide treatment in patients with hepatitis B infection.

Materials and Methods:

The clinical trials have evaluated TAF in НBeAg positive and HBeAg negative HBV patients. The trials have similar design and randomized,Single-blind, the subjects are unaware of which group they have been assigned to studies. The primary efficacy endpoint was the proportion of patients with HBV-DNA<29IU/ml at weeks 96. Other virological result endpoints were the proportion of patients with HBsAg seroconversion at weeks 96.

Results:

The virologic endpoints, an HBV-DNA < 29 IU/ml at weeks 96, was achieved by 243(79.1%) receiving TAF, 111(75.4)% of patients which were non-inferior to the 106(78.5%) patients receiving TDF (95% confidence interval (CI 9.7–2.5); p = 0.26. After of treatment at week 96, significant higher rates of ALT normalization was seen in the TAF group compared to the TDF group (209(68%) "vs" 83(56.4%) "vs" 82(60.8%), p = 0.001) Result: At 96 weeks of treatment, patients receiving TAF hed significantly smaller reductions in bone mineral density(BMD) compared with patients receiving TDF. At weeks 96, median changes in eGFR were signifi-cantly smaller in the TAF recipients compared with the TDF recipients.

Conclusion:

TAF and switching from TDF to TAF are similar efficacy and safety in long-term treatment of TDF.

Biography

To be updated soon...

4th International Conference on Cardiology

Tuvshinbayar N

Title: Clinical and virusological outcomes of tenofovir alafenamide treatment in patients with Hepatitis B virus infection

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at